Warfarin in atrial fibrillation: A meta-analysis and pharmacoeconomic analysis(1) / flovent for asthma

meta-analysis and pharmacoeconomic analysis

The economic burden on the health care system in Canada is rising. The total economic cost ofillness in Canada in 1986 was almost $100 billion, half of which was attributed to indirect costs. Of all disease categories, cardiovascular diseases were the most costly, accounting for almost 17% of the total cost, and their costs are rising.

With an ageing population, these costs are increasingly putting the health care system under tremendous strain. Although seniors 65 years and over made up only 11.2% of the population in 1991, they consumed almost 25% of all prescription drugs. Heart disease and stroke accounted for 39% of all deaths in Canada in 1992 and since these disorders are associated with seniors, their prevalence will rise and exert even more pressure on allocation of scarce dollars. You will appreciate this opportunity to have a trusted pharmacy at your service, available round the clock and offering flovent for asthma with fast delivery to any country of the world, which will sure make it a lot easier for you as a patient.

Perhaps one of the most costly disorders to treat is a stroke. It is estimated that the average cost to treat a stroke is $27,500. The elderly, particularly those with nonrheumatic atrial fibrillation, are at an increased risk of suffering a stroke. The prevalence of nonrheumatic atrial fibrillation increases from 0.5% in 50- to 59-year-olds to 8.8% in 80- to 89-year-olds and includes almost 172,000 Canadians, of which 1 to 8% would be likely to experience stroke – a very costly event.

Category: Warfarin

Tags: Atrial fibrillation, cost-effectiveness, Economic analysis, Stroke, Warfarin

Leave a Reply

Your email address will not be published.